Arcutis Biotherapeutics, Inc.

The Company evaluates its available-for-sale debt securities and accounts receivable for expected credit losses at each reporting date.

SEC original ↗Arcutis Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Fair Value Measurement The Company s financial instruments, in addition to those presented in Note 4, include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and long-term debt.

SEC original ↗Arcutis Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

As the long-term debt is subject to variable interest rates that are based on market rates which regularly reset, the Company believes that the carrying value of the long-term debt approximates its fair value.

SEC original ↗Arcutis Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Treasury and agency securities 93,730 93,730 Total assets $ 122,388 $ 116,164 $ $ 238,552 December 31, 2025 Level 1 Level 2 Level 3 Total Assets: Money market funds and cash $ 37,541 $ $ $ 37,541 Certificates of deposit 5,366 5,366 Commercial paper 14,789 14,789 Corporate debt securities 78,764 78,764 U.

SEC original ↗Arcutis Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Commercial paper and corporate debt securities are valued taking into consideration valuations obtained from third-party pricing services.

SEC original ↗Arcutis Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Treasury and agency securities 93,856 ( 126 ) 93,730 Total marketable securities $ 204,765 $ 1 $ ( 335 ) $ 204,431 December 31, 2025 Amortized cost Unrealized gains Unrealized losses Estimated fair value Cash and cash equivalents: Money market funds and cash $ 37,541 $ $ $ 37,541 Certificates of deposit 5,366 5,366 Total cash and cash equivalents $ 42,907 $ $ $ 42,907 Marketable securities: Commercial paper $ 14,782 $ 8 $ ( 1 ) $ 14,789 Corporate debt securities 78,687 81 ( 4 ) 78,764 U.

SEC original ↗Arcutis Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

(Nasdaq ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended June 30, 2025, and provided a business update.

SEC original ↗Arcutis Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

We continue to advance our strategy to become the leading medical dermatology company.

SEC original ↗Arcutis Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Looking ahead, we remain focused on expanding the approved uses of ZORYVE to the youngest patients, with the potential Q4 approval of ZORYVE cream 0.05% for 2 to 5 year olds with atopic dermatitis and the initiation of an infant atopic dermatitis study.

SEC original ↗Arcutis Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

In addition, the Company commenced a four-week Phase 2 study to evaluate investigational, once-daily ZORYVE cream 0.05% in infants as young as 3 months to less than 2 years with atopic dermatitis, which could potentially be the basis for further indication expansion.

SEC original ↗Arcutis Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

While clinical and biomarker results indicated some level of efficacy, the results did not meet the Company's threshold for advancement, and the Company has deprioritized the program given other R D priorities across its portfolio.

SEC original ↗Arcutis Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

ZORYVE foam - a once-daily foam formulation of topical roflumilast designed to overcome the challenges of delivering topical drugs in hair-bearing areas of the body, approved in the United States for the treatment of seborrheic dermatitis and plaque psoriasis of the scalp and body.

SEC original ↗Arcutis Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases.

SEC original ↗Arcutis Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements.

SEC original ↗Arcutis Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing, expenses, and success of our commercialization efforts, including uncertainty of future commercial sales and related items that can impact net sales, and our ability to defend our intellectual property.

SEC original ↗Arcutis Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

For a further description of the risks and uncertainties applicable to our business, see the Risk Factors section of our Form 10-K filed with U.

SEC original ↗Arcutis Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed in Part II, Item 1A, Risk Factors in this Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

SEC original ↗Arcutis Biotherapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026